Abiopharma

🔍 SHEPARD WILLIAM R (Director)

Company: CME GROUP INC. (CME)

Report Date: 2026-06-25

Detailed Transactions and Holdings:

• Acquired 645 shares of Common Stock Class A at $225.0 per share (Direct)
  Date: 2026-06-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,184.45 | transaction_form_type: 4 | Footnotes: F1
• Acquired 422 shares of Common Stock Class A at $225.0 per share (Direct)
  Date: 2026-06-25 | Code: A | equity_swap_involved: 0 | shares_owned_after: 3,606.45 | transaction_form_type: 4 | Footnotes: F2
• Acquired 14 shares of Common Stock Class A at $230.57 per share (Direct)
  Date: 2026-06-25 | Code: P | equity_swap_involved: 0 | shares_owned_after: 3,620.77 | transaction_form_type: 4 | Footnotes: F3
• Acquired 325 shares of Common Stock Class A at $230.57 per share (Direct)
  Date: 2026-06-25 | Code: P | equity_swap_involved: 0 | shares_owned_after: 260,442.32 | transaction_form_type: 4 | Footnotes: F3

Footnotes:

• F1: Represents a grant of fully vested shares of Class A Common Stock issued to the Reporting Person as part of the Issuer's annual equity compensation program for non-employee directors under the CME Group Director Stock Plan. These shares are not subject to any vesting conditions.
• F2: At the Reporting Person's election, shares issued in lieu of all or a portion of the annual cash retainer for serving as a member of the Board of Directors. The number of shares was determined by dividing the cash retainer by the closing price on the date of grant.
• F3: Represents shares acquired pursuant to a broker-administered dividend reinvestment plan.